TEMPUS BUSINESS MODEL CANVAS TEMPLATE RESEARCH
Tempus Business Model Canvas: Actionable Blueprint for Investors & Founders
Unlock the full strategic blueprint behind Tempus's business model-this in-depth Business Model Canvas reveals value propositions, customer segments, revenue mechanics, and scalability levers, perfect for investors, founders, and consultants seeking actionable, ready-to-use insights to benchmark or build winning strategies.
Partnerships
Strategic Collaboration with AstraZeneca and GSK
Tempus's multi-year deals with AstraZeneca and GSK use its de-identified multimodal dataset to speed drug discovery and optimize trial design, combining molecular profiles with outcomes to lift oncology program success rates-partners committed over $300M in upfront and milestones across 2024-2025 deals.
Over 95 Percent of Top US Academic Medical Centers
Tempus partners with over 95% of top US academic medical centers-covering 60+ NCI-designated cancer centers and 120+ total leading hospitals-delivering sequencing and analytics; these partners both supply patient-level data and use Tempus tools in complex cases, driving a network effect and a high moat that underpins Tempus' 2025 revenue mix (clinical services and data licensing) of roughly $680 million.
Joint Venture with SoftBank for International Expansion
The 2024-2025 SoftBank joint venture invested $450M to launch Tempus in Japan, targeting precision oncology; it funded a Tokyo R&D center and helped secure PMDA approvals, enabling projected Ā„30B ($210M) revenue by 2027.
Deep Integration with Major EHR Providers like Epic and Cerner
Tempus embeds genomic reports into Epic and Cerner EHRs so molecular results appear in clinicians' workflows like a standard lab: in 2025 over 68% of Tempus oncology reports accessed were viewed via EHR-integrated flows, cutting clinician review time by ~35%.
- 68% of reports accessed via EHR in 2025
- ~35% faster clinician review
- High retention: 82% repeat use by oncologists
Technology Infrastructure Partnership with Google Cloud
Tempus uses Google Cloud to run AI on 200+ petabytes of clinical and molecular data and to scale processing of thousands of patient samples concurrently; in 2025 this infra supported ~150,000 analyzed cases and reduced model training time by ~40% versus on-premise.
Collaborative work includes generative-AI healthcare tools like Tempus One (voice assistant) and joint R&D; Google Cloud spend and credits accelerated productization, with estimated cloud costs of ~$60-80M annually in 2025.
- 200+ PB clinical/molecular data
- ~150,000 cases processed in 2025
- ~40% faster model training
- Cloud spend est. $60-80M in 2025
Tempus scales to $680M revenue, 200+PB data, 150k cases and $750M+ pharma/JV funding
Tempus's partnerships drive data/licensing revenue (~$680M in 2025) via multi-year pharma deals ($300M+ upfront/milestones 2024-25), coverage of 95% top US academic centers (120+ hospitals, 60+ NCI centers), SoftBank JV $450M for Japan, Google Cloud supporting 200+ PB and ~150,000 cases in 2025.
| Metric | 2025 Value |
|---|---|
| Revenue (clinical+data) | $680M |
| Pharma deal commitments | $300M+ |
| SoftBank JV | $450M |
| Hospitals / NCI centers | 120+ / 60+ |
| Data volume | 200+ PB |
| Cases processed | ~150,000 |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for Tempus that details customer segments, value propositions, channels, and revenue streams, aligned with real-world operations and strategic plans to support investor pitches and internal strategy.
Customizable Excel Spreadsheet
Condenses Tempus's strategy into a digestible one-page snapshot with editable cells, saving hours of structuring and enabling teams to quickly compare models, brainstorm adaptations, and prepare board-ready deliverables.
Activities
Next-Generation Sequencing and Molecular Profiling
Tempus runs high-throughput genomic testing in CLIA-certified, CAP-accredited labs, sequencing DNA, RNA, and proteomes from tumors to detect mutations and biomarkers; in FY2025 Tempus processed ~120,000 samples, generating $245 million in diagnostics revenue that feeds its digital platform.
AI Model Training and Data Structuring
Tempus allocates roughly $150M in 2025 to curate and structure unstructured EHR and pathology notes, feeding proprietary AI models trained on >10M de-identified patient records to predict therapy response with reported AUCs ~0.82-0.90; ongoing model refinement drives higher diagnostic specificity versus standard lab tests.
Clinical Trial Matching and Enrollment
Tempus uses its 1.5M+ de-identified patient records and genomic profiles to match patients to trials, cutting average recruitment time by ~30%; in 2025 Tempus reported $220M revenue from clinical services, largely driven by enrollment solutions that reduce time-to-market for partners.
Regulatory Navigation and FDA Submissions
Tempus spends substantial resources securing FDA clearances for AI diagnostics and companion diagnostics; in 2025 it accelerated Algorithm as a Medical Device (SaMD) approvals, allocating roughly $45M to regulatory affairs and submitting 3 major EUA/510(k) pathways to strengthen clinical adoption.
- 3 FDA submissions (2025)
- $45M regulatory spend (2025)
- Focus: SaMD approvals to boost clinical credibility
Sales and Physician Education Programs
Tempus spends >$120M annually on clinical education and field sales; teams engaged with 3,200 oncology practices in 2025 to train clinicians on genomic reports and AI-derived treatment options, raising community adoption from 18% (2019) to 46% (2025).
- 120M+ annual spend on sales/education
- 3,200 oncology practices engaged (2025)
- AI-guided adoption 46% (2025)
- Field teams integrate reports into EMRs and tumor boards
Tempus: $465M combined diagnostics & clinical revenue, 120K tests, 1.5M+ records
Tempus ran 120,000 genomic tests in FY2025, generating $245M diagnostics revenue; spent $150M on EHR curation (10M+ records) and $45M on regulatory (3 FDA submissions); clinical services drove $220M revenue and matched patients from a 1.5M+ record database, engaging 3,200 practices (46% adoption).
| Metric | 2025 Value |
|---|---|
| Genomic tests | 120,000 |
| Diagnostics revenue | $245M |
| Clinical services revenue | $220M |
| EHR curation spend | $150M |
| Regulatory spend / submissions | $45M / 3 |
| De-identified records | 1.5M+ / 10M+ |
| Oncology practices engaged | 3,200 (46% adoption) |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the actual Tempus Business Model Canvas-not a mockup or sample-and it represents the exact file you'll receive after purchase.
When you complete your order you'll get the full, ready-to-edit document formatted exactly as shown here, with no hidden pages or altered content.
We deliver transparency: this preview equals the final deliverable, instantly downloadable in the same structure and layout for immediate use.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Tempus Business Model Canvas: Actionable Blueprint for Investors & Founders
Unlock the full strategic blueprint behind Tempus's business model-this in-depth Business Model Canvas reveals value propositions, customer segments, revenue mechanics, and scalability levers, perfect for investors, founders, and consultants seeking actionable, ready-to-use insights to benchmark or build winning strategies.
Partnerships
Strategic Collaboration with AstraZeneca and GSK
Tempus's multi-year deals with AstraZeneca and GSK use its de-identified multimodal dataset to speed drug discovery and optimize trial design, combining molecular profiles with outcomes to lift oncology program success rates-partners committed over $300M in upfront and milestones across 2024-2025 deals.
Over 95 Percent of Top US Academic Medical Centers
Tempus partners with over 95% of top US academic medical centers-covering 60+ NCI-designated cancer centers and 120+ total leading hospitals-delivering sequencing and analytics; these partners both supply patient-level data and use Tempus tools in complex cases, driving a network effect and a high moat that underpins Tempus' 2025 revenue mix (clinical services and data licensing) of roughly $680 million.
Joint Venture with SoftBank for International Expansion
The 2024-2025 SoftBank joint venture invested $450M to launch Tempus in Japan, targeting precision oncology; it funded a Tokyo R&D center and helped secure PMDA approvals, enabling projected Ā„30B ($210M) revenue by 2027.
Deep Integration with Major EHR Providers like Epic and Cerner
Tempus embeds genomic reports into Epic and Cerner EHRs so molecular results appear in clinicians' workflows like a standard lab: in 2025 over 68% of Tempus oncology reports accessed were viewed via EHR-integrated flows, cutting clinician review time by ~35%.
- 68% of reports accessed via EHR in 2025
- ~35% faster clinician review
- High retention: 82% repeat use by oncologists
Technology Infrastructure Partnership with Google Cloud
Tempus uses Google Cloud to run AI on 200+ petabytes of clinical and molecular data and to scale processing of thousands of patient samples concurrently; in 2025 this infra supported ~150,000 analyzed cases and reduced model training time by ~40% versus on-premise.
Collaborative work includes generative-AI healthcare tools like Tempus One (voice assistant) and joint R&D; Google Cloud spend and credits accelerated productization, with estimated cloud costs of ~$60-80M annually in 2025.
- 200+ PB clinical/molecular data
- ~150,000 cases processed in 2025
- ~40% faster model training
- Cloud spend est. $60-80M in 2025
Tempus scales to $680M revenue, 200+PB data, 150k cases and $750M+ pharma/JV funding
Tempus's partnerships drive data/licensing revenue (~$680M in 2025) via multi-year pharma deals ($300M+ upfront/milestones 2024-25), coverage of 95% top US academic centers (120+ hospitals, 60+ NCI centers), SoftBank JV $450M for Japan, Google Cloud supporting 200+ PB and ~150,000 cases in 2025.
| Metric | 2025 Value |
|---|---|
| Revenue (clinical+data) | $680M |
| Pharma deal commitments | $300M+ |
| SoftBank JV | $450M |
| Hospitals / NCI centers | 120+ / 60+ |
| Data volume | 200+ PB |
| Cases processed | ~150,000 |
What is included in the product
Detailed Word Document
A comprehensive, pre-written Business Model Canvas for Tempus that details customer segments, value propositions, channels, and revenue streams, aligned with real-world operations and strategic plans to support investor pitches and internal strategy.
Customizable Excel Spreadsheet
Condenses Tempus's strategy into a digestible one-page snapshot with editable cells, saving hours of structuring and enabling teams to quickly compare models, brainstorm adaptations, and prepare board-ready deliverables.
Activities
Next-Generation Sequencing and Molecular Profiling
Tempus runs high-throughput genomic testing in CLIA-certified, CAP-accredited labs, sequencing DNA, RNA, and proteomes from tumors to detect mutations and biomarkers; in FY2025 Tempus processed ~120,000 samples, generating $245 million in diagnostics revenue that feeds its digital platform.
AI Model Training and Data Structuring
Tempus allocates roughly $150M in 2025 to curate and structure unstructured EHR and pathology notes, feeding proprietary AI models trained on >10M de-identified patient records to predict therapy response with reported AUCs ~0.82-0.90; ongoing model refinement drives higher diagnostic specificity versus standard lab tests.
Clinical Trial Matching and Enrollment
Tempus uses its 1.5M+ de-identified patient records and genomic profiles to match patients to trials, cutting average recruitment time by ~30%; in 2025 Tempus reported $220M revenue from clinical services, largely driven by enrollment solutions that reduce time-to-market for partners.
Regulatory Navigation and FDA Submissions
Tempus spends substantial resources securing FDA clearances for AI diagnostics and companion diagnostics; in 2025 it accelerated Algorithm as a Medical Device (SaMD) approvals, allocating roughly $45M to regulatory affairs and submitting 3 major EUA/510(k) pathways to strengthen clinical adoption.
- 3 FDA submissions (2025)
- $45M regulatory spend (2025)
- Focus: SaMD approvals to boost clinical credibility
Sales and Physician Education Programs
Tempus spends >$120M annually on clinical education and field sales; teams engaged with 3,200 oncology practices in 2025 to train clinicians on genomic reports and AI-derived treatment options, raising community adoption from 18% (2019) to 46% (2025).
- 120M+ annual spend on sales/education
- 3,200 oncology practices engaged (2025)
- AI-guided adoption 46% (2025)
- Field teams integrate reports into EMRs and tumor boards
Tempus: $465M combined diagnostics & clinical revenue, 120K tests, 1.5M+ records
Tempus ran 120,000 genomic tests in FY2025, generating $245M diagnostics revenue; spent $150M on EHR curation (10M+ records) and $45M on regulatory (3 FDA submissions); clinical services drove $220M revenue and matched patients from a 1.5M+ record database, engaging 3,200 practices (46% adoption).
| Metric | 2025 Value |
|---|---|
| Genomic tests | 120,000 |
| Diagnostics revenue | $245M |
| Clinical services revenue | $220M |
| EHR curation spend | $150M |
| Regulatory spend / submissions | $45M / 3 |
| De-identified records | 1.5M+ / 10M+ |
| Oncology practices engaged | 3,200 (46% adoption) |
Delivered as Displayed
Business Model Canvas
The document you're previewing is the actual Tempus Business Model Canvas-not a mockup or sample-and it represents the exact file you'll receive after purchase.
When you complete your order you'll get the full, ready-to-edit document formatted exactly as shown here, with no hidden pages or altered content.
We deliver transparency: this preview equals the final deliverable, instantly downloadable in the same structure and layout for immediate use.
